197507-22-5

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-FLUORO-4-HYDROXYBENZOATE is used as an intermediate in the synthesis of 3-(2-fluoro-4-hydroxyphenyl)-5-(trifluoromethyl)-4-isoxazolecarboxylic acid methyl ester (F591865), a compound with potential applications in the treatment of various diseases and conditions.
Used in Chemical Research:
METHYL 2-FLUORO-4-HYDROXYBENZOATE is used as a research compound for studying its properties and potential applications in various fields, including the development of new drugs and materials.
Used in Compound Preparation:
METHYL 2-FLUORO-4-HYDROXYBENZOATE is used in the preparation of compounds that can inhibit cytosolic phospholipase A2α, an enzyme involved in various inflammatory processes. This makes it a valuable component in the development of anti-inflammatory drugs and other therapeutic agents.

InChI:InChI=1/C8H7FO3/c1-12-8(11)6-3-2-5(10)4-7(6)9/h2-4,10H,1H3

Upstream product

• 65145-13-3 2-fluoro-4-hydroxybenzoic acid 
• 67-56-1 methanol 
• 331-64-6 2-fluoro-4-methoxy-benzaldehyde 
• 394-42-3 2-fluoro-4-methoxy-benzoic acid 
• 148893-72-5 4-chloro-2-fluorobenzoic acid methyl ester 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 

Downstream Products

• 872674-85-6 methyl 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]-2-fluorobenzoate 
• 884658-60-0 2-fluoro-4-(furan-2-ylmethoxy)-benzoic acid methyl ester 
• 884658-58-6 2-fluoro-4-(thiazol-4-ylmethoxy)-benzoic acid methyl ester 
• 1037754-87-2 methyl 2-fluoro-4-(3-(1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl)propoxy)benzoate 
• 957205-33-3 methyl 2-fluoro-4-(((trifluoromethyl)sulfonyl)oxy)benzoate 
• 1142227-35-7 5-bromo-2-fluoro-4-hydroxybenzoic acid methyl ester 
• 1221179-04-9 methyl 4-(benzyloxy)-2-fluorobenzoate 
• 1190044-36-0 C₁₃H₁₅FO₃ 
• 1321938-00-4 2-fluoro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoic acid 
• 1321938-25-3 2-fluoro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl chloride 
• 502606-27-1 benzyl [1-(2-fluoro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl)-2-methyl-1H-indol-3-yl]acetate 
• 502606-38-4 benzyl [5-fluoro-1-(2-fluoro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl)-2-methyl-1H-indol-3-yl]acetate 
• 1321937-76-1 methyl 2-fluoro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoate 
• 1224719-48-5 2-fluoro-4-[(2S)-tetrahydrofuran-2-ylmethoxy]benzoic acid 

Relevant academic research and scientific papers

NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by

Synthesis and Mesomorphic Properties of Novel Bent-shaped Naphthyl Diketones

The synthesis and liquid-crystalline properties are reported for novel naphthyl-based diketones incorporating variant terminal chains and lateral fluoro- substitution. Newly prepared materials exhibit a broad temperature range of the nematic phase. The study demonstrates how subtle structural modifications can be exploited to alter the efficiency of molecular packing and consequently the thermal behaviour.

Synergistic Photo-Copper-Catalyzed Hydroxylation of (Hetero)aryl Halides with Molecular Oxygen

Photoredox-mediated copper-catalyzed hydroxylation of (hetero)aryl halides (including chlorides, bromides, and iodides) with O2 at room temperature has been developed. Preliminary mechanistic studies indicate no arylcopper intermediate and that aryl radicals are involved in this procedure. 18O-labeling experiments confirm the hydroxyl oxygen atom originated from molecular oxygen.

Hydrogen-bonded bent-core blue phase liquid crystal complexes containing various molar ratios of proton acceptors and donors

Various hydrogen-bonded (H-bonded) bent-core liquid crystal complexes consisting of pyridyl and benzoic acid derivatives were synthesized and compared with their covalent analogues in this study. The molar ratios of pyridyl and benzoic acid derivatives could be tuned to form various H-bonded liquid crystal (LC) diads (with 1:1 molar ratio of H-acceptors T and H-donors D) and complexes (with different molar ratios of T and D). By insertion of H-bonds into different positions of bent-core supramolecules, the mesophasic properties of H-bonded bent-core LC complexes were optimized, which could facilitate the most suitable LC components and compositions to be utilized in H-bonded blue phase (BP) LC complexes. In BPLC complexes, the molar ratios, alkyl chain lengths, the lateral fluoro-substitution and the chiral center of H-bonded bent-core supramolecules would affect the temperature ranges of BPs. Accordingly, H-bonded bent-core complex PIIIC9/AIIF? (3/7 mol mol-1) displayed the widest BPI range of ΔTBPI = 12.0 °C at the correspondent H-acceptor T = PIIIC9 and H-donor D = AIIF?. Since the covalent-bonded bent-core mixture only had narrow ranges of BPIII, we could summarize that the introduction of H-bonds into the bent-core center effectively stabilizes the BPs and easier induces the BPI.

Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these

INDOLE DERIVATIVE

The present invention provides an indole derivative having a melanin-concentrating hormone receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

QUINOLINE DERIVATIVE

The present invention provides a compound having a melanin-concentrating hormone receptor antagonistic action and low toxicity, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

SPIROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.